C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab, the first developed monoclonal antibody inhibiting C5‐cleavage and preventing the formation of the terminal complement complex C5b‐C9, has demonstrated long‐term safety and efficacy in the treatment of PNH [6, 7, 8].